Research programme: interstitial cystitis therapeutics - Acologix/University of Maryland

Drug Profile

Research programme: interstitial cystitis therapeutics - Acologix/University of Maryland

Alternative Names: AC-700

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator University of Maryland, Baltimore
  • Class Glycoproteins
  • Mechanism of Action Antiproliferative factor APF inhibitors; Heparin epidermal growth factor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Interstitial cystitis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Interstitial-cystitis in USA
  • 28 Feb 2007 AC 700 is available for licensing worldwide(http://www.acologix.com)
  • 19 Sep 2006 Preclinical trials in Interstitial cystitis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top